Our Mission: Cure Autoimmune Disease
At Parvus, we are developing proprietary novel pMHC nanomedicine drug candidates which trigger in vivo generation of antigen-specific regulatory T cells (Tregs) with the potential to halt and cure autoimmune disease by restoring organ specific immune tolerance without compromising normal immune function.
The pMHC Nanomedicine Platform
Current approaches to treating autoimmune disease require broad suppression of the immune system to prevent the immune system from attacking a patient’s own tissue (self). In contrast, our pMHC nanomedicine platform generates disease specific regulatory T cells (Tregs) in vivo which reverse autoimmune disease by suppressing autoimmune attacks on self without impairing normal immune function.
About Parvus
Parvus is a clinical-stage company developing novel proprietary pMHC nanomedicine drug candidates as treatments for patients who suffer from autoimmune disease. Our research and development is based on the discoveries of Pere Santamaria, M.D., Ph.D., Professor in the Department of Microbiology & Infectious Diseases and Julia McFarlane Chair in Diabetes Research at the Cumming School of Medicine at the University of Calgary.